An experimental drug developed at Michigan Medicine has reversed a serious form of fatty liver disease in animal studies by targeting an unexpected source of liver damage: the gut. The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage.
DT-109 Targets Gut Bacteria to Protect the Liver
MASH affects approximately 7% of the world’s population. It is a severe form of fatty liver disease in which excess fat accumulates in the liver, causing inflammation and cellular damage. Over time, the condition can progress to cirrhosis, which involves extensive liver scarring, as well as liver cancer and liver failure. Although treatment options have improved in recent years, effective therapies remain limited.
Eugene Chen, M.D., Ph.D., senior author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School, stated that the research provides clear evidence that DT-109 protects the gut epithelial barrier. This protection reduces the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression. Chen noted that the compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH.
Chen’s research team had previously demonstrated that DT-109, a glycine-based tripeptide, could improve MASH in animal studies. A tripeptide is a small molecule made from three amino acids, which are the building blocks of proteins. What remained unclear was exactly how the compound produced its protective effects. The latest research provides an explanation, revealing how changes in gut bacteria can set off a chain reaction that damages the liver and how DT-109 can interrupt that process.
Restoring the Intestinal Barrier
Before examining the drug’s effects, the scientists confirmed an important contributor to MASH: excessive growth of Clostridium perfringens, a bacterium that produces ammonia inside the intestines. When ammonia levels rise, they can damage the gut’s protective inner lining. Normally, this intestinal barrier helps prevent potentially harmful substances from escaping the digestive tract and entering the bloodstream.
As the barrier weakens, however, toxins and other products generated by gut microbes can travel to the liver. Once there, they can provoke inflammation and activate immune defenses in ways that worsen liver damage. One response involves the excessive activation of CD8+ T cells, immune cells that normally help the body destroy infected or abnormal cells. When these cells become overactive, they can contribute to the inflammatory processes associated with MASH.
Through a series of experiments, researchers discovered that DT-109 disrupts this damaging cycle by improving the intestinal environment and reinforcing the gut’s protective barrier. In both mice and nonhuman primates, the compound reduced levels of Clostridium perfringens and lowered ammonia production in the intestines. These changes helped strengthen the intestinal lining, limiting the movement of harmful microbial substances into the body and reducing their potential to damage the liver.
The results were particularly encouraging in nonhuman primates, whose liver biology and gut microbial communities more closely resemble those of humans than those of mice. In these animals, DT-109 reduced liver inflammation and lessened the severity of MASH. Together, the findings show how targeting harmful processes in the gut can produce beneficial effects in the liver, even though the drug acts primarily within the gastrointestinal system.
Future Clinical Trials and Broader Applications
Jifeng Zhang, Ph.D., co-author and research professor of cardiovascular medicine at U-M Medical School, explained that DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis. He added that while DT-109 primarily acts in the gastrointestinal tract, its reach stretches much further.
The gut-liver axis refers to the close biological relationship between the digestive tract and the liver. Substances absorbed from the intestines travel to the liver through the bloodstream, making liver health particularly sensitive to changes in gut bacteria and intestinal barrier function. By targeting this connection, DT-109 may offer a way to address some of the processes driving liver inflammation rather than focusing exclusively on damage that has already occurred.
Researchers believe the compound’s ability to protect the intestinal barrier could make it useful against other conditions involving inflammation and metabolic dysfunction. Previous research has shown that DT-109 can reduce the formation of atherosclerotic plaques and prevent vascular calcification in nonhuman primates. These findings suggest that DT-109 could eventually have applications in treating both liver and cardiovascular conditions, an important possibility because metabolic disorders often affect multiple organs.
Despite the encouraging results, DT-109 remains an experimental treatment. Its ability to reverse MASH has been demonstrated in animal models, but researchers have not yet established whether it can safely and effectively produce similar benefits in humans. The next phase of research will involve further evaluation of the compound, with the goal of advancing it toward clinical trials. Those studies will be essential for determining its safety, appropriate use, and potential effectiveness in patients.
Source: ScienceDaily
